GLOW, Wolverine, and KLOW sound like defined formulations, but they are market names rather than pharmacopoeial or regulatory standards. Their meaning comes from dated listings, and listings using the same name can differ in component form or claimed composition.
The blend atlas records that instability without treating a seller claim as proof of identity, quality, clinical benefit, or mixture-specific evidence.
How market names become unstable
The current blend pages record these commonly claimed component families:
| Name | Components commonly claimed | Documented variant | Standardization | Combination evidence |
|---|---|---|---|---|
| Wolverine | BPC-157 + TB-500 | Listings vary in presentation and component claims | None identified | No controlled comparison of the mixture against its components |
| GLOW | GHK-Cu + BPC-157 + TB-500 | Dated listings report different claimed proportions | None identified | No peer-reviewed study of the named triple combination |
| KLOW | GHK-Cu + KPV + BPC-157 + TB-500 | Dated listings vary and the TB-500 identity remains ambiguous | None identified | No published study of the named four-component combination |
| KLOW70 | GHK-Cu + KPV + BPC-157 in the documented variant | The current KLOW page records a variant that omits TB-500 | None identified | No mixture-specific study identified |
A shared label therefore does not guarantee shared composition. TB-500 adds a second ambiguity because the market name can refer to materially different entities; the TB-500 monograph preserves that boundary.
The diagram and table show market association only. They do not verify what was present in any physical sample.
| Name | GHK-Cu | BPC-157 | TB-500 | KPV |
|---|---|---|---|---|
| Wolverine | Not in documented row | Commonly claimed | Commonly claimed | Not in documented row |
| GLOW | Commonly claimed | Commonly claimed | Commonly claimed | Not in documented row |
| KLOW | Commonly claimed | Commonly claimed | Commonly claimed | Commonly claimed |
| KLOW70 | Commonly claimed | Commonly claimed | Not in documented row | Commonly claimed |
Evidence transfer
Separate component research is not a study of the named mixture. The BPC-157, GHK-Cu, KPV, and TB-500 pages evaluate different identities, claims, models, and limitations.
Combining those narratives cannot establish mixture synergy, interactions, stability, or clinical benefit. A mechanistic rationale remains a hypothesis until the exact combination is tested in a design that can answer the combination claim.
Quality limits
A listing can document how a name is marketed. A seller-provided certificate can document what that certificate claims. Neither alone establishes complete identity, purity, sterility, strength, stability, or authenticity.
Those quality attributes require different methods and reference standards, as explained in Product quality, authenticity, and testing. Evidence for one attribute cannot be silently generalized to every other attribute.
What the atlas captures
For each observed claim, the atlas records the name, exact claimed components and forms, source, date, and verification limits. Quantitative listing examples remain on the dated Wolverine, GLOW, and KLOW pages instead of being repeated here.
What the atlas cannot establish from market records is equally important: actual sample identity, manufacturing quality, combination efficacy, compatibility, or suitability.
Reading blend claims with precision
Compare exact component names and forms, not just the headline label. Record the source and date. Check whether a variant omits or changes a component. Then keep component evidence, mixture evidence, product quality, regulatory status, and The World Anti-Doping Agency; its Prohibited List classifies many peptides as prohibited substances in sport. Fuente de la definición: WADA and sport regulation brief · Glosario status in separate lanes.
If those details are missing, the most defensible conclusion is that the marketed name is underspecified.